Team Pontus Nauclér

Research focus

Targeted antibiotic therapy of patients with severe infections to improve clinical impact and reduce resistance.

Introduction

We live in a world of increasingly scarce resources when it comes to antibiotics. The World Health Organization estimates 700 000 deaths from antibiotic resistance yearly that could rise to 10 million per year by 2050.  Misuse of antibiotics accelerates development and spread of drug-resistance. Improved strategies of antibiotic treatment in patients with severe infections are urgently needed to improve survival and to reduce unnecessary usage of antibiotics that leads to resistance development.

Major research focus

We combine large databases of clinical and microbiological data to study 1) the impact of antibiotic treatment and vaccine strategies, 2) screening algorithms to guide antibiotic treatment, and 3) genetic properties of bacteria that can be exploited for future therapeutic interventions. We primarily focus on healthcare-associated infections, pneumonia and gram-negative infections. The studies are performed within test-beds of electronic health records, national register-based research databases of infections, and clinical studies performed in collaboration with national and international researchers. Currently we lead a Vinnova-financed triple-helix project (academia, public partners, and industry) to develop novel big-data driven techniques to curb healthcare-associated infections.

Team members

Pontus Nauclér, MD, PhD, Assosiate Professor, Team Leader

Joakim Isendahl, PhD Student

Samuel Rhedin, MD,PhD student

John Karlsson-Valik, MD, PhD student

Andreas Berge, MD, PhD, Senior Physician

Key publications

Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Rhedin S, Galanis I, Granath F, Ternhag A, Hedlund J, Spindler C, et al
Clin. Microbiol. Infect. 2017 Apr;23(4):247-252

Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study.
Ny S, Löfmark S, Börjesson S, Englund S, Ringman M, Bergström J, et al
J. Antimicrob. Chemother. 2017 Feb;72(2):582-588

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, et al
Eur. Respir. J. 2016 Apr;47(4):1208-18

Betamethasone and dexamethasone in adult community-acquired bacterial meningitis: a quality registry study from 1995 to 2014.
Glimåker M, Brink M, Naucler P, Sjölin J
Clin. Microbiol. Infect. 2016 Sep;22(9):814.e1-814.e7

Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study.
Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Öhrmalm L, Tolfvenstam T, et al
Thorax 2015 Sep;70(9):847-53

Prevalence of community-acquired bacteraemia in Guinea-Bissau: an observational study.
Isendahl J, Manjuba C, Rodrigues A, Xu W, Henriques-Normark B, Giske C, et al
BMC Infect. Dis. 2014 Dec;14():3859

Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia.
Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B
Thorax 2013 Jun;68(6):571-9